Get the Stockscreener App
63.35
4.25%
2.58
Cytokinetics Inc stock is traded at $63.35, with a volume of 1.62M.
It is up +4.25% in the last 24 hours and down -3.93% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$60.77
Open:
$60.99
24h Volume:
1.62M
Relative Volume:
0.81
Market Cap:
$7.75B
Revenue:
$18.47M
Net Income/Loss:
$-589.53M
P/E Ratio:
-12.04
EPS:
-5.26
Net Cash Flow:
$-399.80M
1W Performance:
-3.53%
1M Performance:
-3.93%
6M Performance:
+90.81%
1Y Performance:
+26.11%
1-Day Range:
$60.45
$63.80
1-Week Range:
$59.56
$66.37
52-Week Range:
$29.31
$69.33
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
63.35 | 7.43B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | Raymond James | Mkt Perform |
| Apr-24-25 | Initiated | Barclays | Overweight |
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Frazier Life Sciences Management L.P. Invests $18.33 Million in Cytokinetics, Incorporated $CYTK - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
EMA’s CHMP backs new medicines from Hansoh, Cytokinetics - BioCentury
Cytokinetics receives positive EU opinion for MYQORZO in heart condition By Investing.com - Investing.com Canada
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. ... - Bakersfield.com
Notice to Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf - GlobeNewswire Inc.
CHMP recommends Immunitybio's Anktiva, Cytokinetics' Myqorzo - BioWorld MedTech
EMA committee recommends approval of Cytokinetics’ oHCM drug - Investing.com
Cytokinetics (CYTK) Receives Positive EU Recommendation for MYQO - GuruFocus
EMA committee recommends approval of Cytokinetics’ oHCM drug By Investing.com - Investing.com Australia
Cytokinetics receives positive EU opinion for MYQORZO in heart condition - Investing.com
Cytokinetics Receives Positive Opinion for MYQORZO® in EU - TradingView — Track All Markets
Cytokinetics Announces Positive CHMP Opinion Of MYQORZO For The Treatment Of Obstructive Hypertrophic Cardiomyopathy - TradingView — Track All Markets
Cytokinetics (Nasdaq: CYTK) gains positive CHMP view on MYQORZO oHCM therapy, EU ruling expected in Q1 2026 - Stock Titan
Cytokinetics (CYTK) Stock Rating Reiterated at 'Buy' by Needham - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Notice For Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire
Andrew Callos Sells 1,042 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Insider Selling: Andrew Callos Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus
Callos Andrew, Cytokinetics EVP, sells $68,730 in shares - Investing.com
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares - sharewise.com
Norges Bank Invests $39.12 Million in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics, Incorporated $CYTK Shares Bought by CW Advisors LLC - MarketBeat
Cytokinetics (CYTK) Valuation Check After Shareholder Investigation Into Aficamten FDA Review Disclosures - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Investors to Inquire about Securities Investigation - ACCESS Newswire
Is Shareholder Probe Into FDA Disclosures Reshaping the Investment Case for Cytokinetics’ Aficamten Story (CYTK)? - simplywall.st
Brown Advisory Inc. Has $32.89 Million Stake in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics (NASDAQ:CYTK) EVP Sells $3,461,451.70 in Stock - MarketBeat
Callos Andrew, Cytokinetics EVP, sells $3.46m in stock By Investing.com - Investing.com South Africa
Insider Sell: Andrew Callos Sells 52,486 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Callos Andrew, Cytokinetics EVP, sells $3.46m in stock - Investing.com India
Why Is Cytokinetics (CYTK) Up 10.4% Since Last Earnings Report? - sharewise.com
Will Cytokinetics Incorporated (KK3A) stock issue positive guidanceJuly 2025 Price Swings & Reliable Momentum Entry Alerts - Newser
Can Cytokinetics Incorporated (KK3A) stock double in coming years2025 Earnings Impact & Weekly Market Pulse Updates - Newser
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Investors to Reach Out - ACCESS Newswire
Is Cytokinetics Incorporated (KK3A) stock overpriced at current multiplesMarket Trend Report & Long-Term Capital Growth Ideas - Newser
Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. ... - Bakersfield.com
Attention Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire
Cytokinetics, Incorporated $CYTK Shares Sold by Schroder Investment Management Group - MarketBeat
Why analysts recommend Cytokinetics Incorporated (KK3A) stockJuly 2025 Market Mood & Low Drawdown Investment Strategies - Newser
What technical patterns form on Cytokinetics Incorporated (KK3A) stock chartsPortfolio Risk Summary & Short-Term Swing Trade Alerts - Newser
How Cytokinetics Incorporated (KK3A) stock trades under stagflation2025 Fundamental Recap & Daily Stock Momentum Reports - Newser
Cytokinetics, Incorporated $CYTK Position Increased by American Century Companies Inc. - MarketBeat
Cytokinetics (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 2,200 Shares - MarketBeat
Henderson, Cytokinetics director, sells $559k in stock By Investing.com - Investing.com South Africa
Edward Md Kaye Sells 28,064 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Cytokinetics, Incorporated $CYTK Stake Cut by Skandinaviska Enskilda Banken AB publ - MarketBeat
Can Cytokinetics Incorporated (KK3A) stock sustain margin levelsQuarterly Market Summary & Free High Accuracy Swing Entry Alerts - Newser
Cytokinetics, Incorporated $CYTK Shares Sold by Fisher Asset Management LLC - MarketBeat
Will Cytokinetics Incorporated (KK3A) stock draw ESG focused fundsJuly 2025 Outlook & Weekly High Return Stock Opportunities - Newser
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):